Sugi Predict

Sugi Predict / Compounds / SCHEMBL1730

SCHEMBL1730

SCHEMBL1730

Cc1nn(C)c(Cl)c1[N+](=O)[O-]

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 3/20 0.61
▸ LMNA P02545 1/20 0.47
▸ MAPT P10636 5/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ CHEK1 O14757 1/20 0.42
▸ DAPK3 O43293 1/20 0.42
▸ GRK5 P34947 1/20 0.42
▸ LIMK1 P53667 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8951990 0.82 PKM (0.44) PKMLMNAMAPTALDH1A1TDP1
SCHEMBL2386652 0.79 PKM (0.66) PKMLMNAMAPTALDH1A1TDP1
SCHEMBL19224194 0.78 PKM (0.42) PKMLMNAMAPTALDH1A1TDP1
SCHEMBL11754156 0.78 PKM (0.46) PKMLMNAMAPTALDH1A1MEN1
SCHEMBL28376978 0.77 PKM (0.41) PKMLMNAMAPTALDH1A1TDP1
SCHEMBL11750774 0.77 PKM (0.45) PKMLMNAMAPTALDH1A1MEN1
SCHEMBL4501948 0.76 PKM (1.00) PKMLMNAMAPTALDH1A1TDP1
SCHEMBL2386649 0.76 PKM (0.61) PKMLMNAMAPTALDH1A1TDP1
SCHEMBL4501944 0.76 PKM (0.61) PKMLMNAMAPTALDH1A1TDP1
SCHEMBL13626328 0.76 PKM (0.61) PKMLMNAMAPTALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026103873-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF 杭州百新生物医药科技有限公司 2026-05-21 — — WO disclosed
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 — — US disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 — — WO disclosed
US-RE50082-E1 (5,6-dihydro)pyrimido[4,5-e]indolizines NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) 2024-08-20 — — US disclosed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 — — US disclosed
CN-116535340-A Substituted N-aryl-1-naphthylamine compound, preparation method and pharmaceutical application thereof 中国医学科学院药物研究所 2023-08-04 — — CN disclosed
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 — — US disclosed
EP-4076423-A1 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2022-10-26 — — EP disclosed
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2022-10-20 — — US disclosed
CN-115087440-A TRPML modulators 卡斯玛治疗公司 2022-09-20 — — CN disclosed
CN-1057464-A Pyrazolopyrimidinoneantianginal antianginal agents PFIZER (US) 1992-01-01 — — CN disclosed
US-5008263-A Platelet activating factor antagonists; antiallergens; antiinflammatory agents PFIZER INC. (US) 1991-04-16 — — US disclosed
CN-1045783-A Diaza  class anti-allergy medicament PFIZER (US) 1990-10-03 — — CN disclosed
EP-0389189-A2 Diazepine antiallergy agents Pfizer Limited (GB) 1990-09-26 — — EP disclosed
US-4954164-A Pyrazolesulfonylurea derivatives, preparation thereof, herbicide containing said derivative as active ingredient and herbicidal method by use thereof NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1990-09-04 — — US disclosed
CN-87105777-A Heterogeneous ring compound — 1988-04-06 — — CN disclosed
EP-0255047-A1 3-Aryl uraciles and their use as herbicides CIBA-GEIGY AG (CH) 1988-02-03 — — EP disclosed
EP-0201188-A2 5-Substituted pyrazolo[4,3-d] pyrimidine-7-ones, process for preparing the compounds and pharmaceutical compositions comprising the compounds WARNER-LAMBERT COMPANY (US) 1986-12-17 — — EP disclosed
EP-0087780-A2 Pyrazolesulfonylurea derivative, preparation thereof, herbicide containing said derivative as active ingredient and herbicidal method by use thereof NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1983-09-07 — — EP disclosed
US-4077956-A ANTIINFLAMMATORY, IMMUNOSUPPRESSIVE E. R. SQUIBB & SONS, INC. (US) 1978-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 PKM 4689/4885LMNA 4878/4885MAPT 2356/4885
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 PKM 527/4885LMNA 3324/4885MAPT 1167/4885
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 PKM 2764/4885LMNA 1281/4885MAPT 2934/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 PKM 4689/4885LMNA 4878/4885MAPT 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.